Navigation Links
GenVec to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/8/2011

GAITHERSBURG, Md., Feb. 8, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq:  GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a company overview highlighting recent developments at the 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 2:30 p.m. EST at the Waldorf Astoria Hotel in New York City.

A webcast of Dr. Fischer's presentation will be available both live and on replay.  To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data."  The replay will be available 3 hours after the live presentation and will be accessible for 30 days.

About GenVecGenVec, Inc. is a biopharmaceutical company using superior, proprietary technology to create differentiated vaccines and therapeutics that are developed and commercialized through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the US Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), HSV-2, dengue fever, influenza, HIV, malaria, and foot-and-mouth disease. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.Investor and Media Contact: GenVec, Inc. Douglas J. Swirsky (240) 632-5510 dswirsky@genvec.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
2. GenVec Reports Third Quarter 2009 Financial Results
3. GenVec Announces Third Quarter 2009 Results Conference Call
4. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
5. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
6. GenVec Reports Second Quarter 2009 Financial Results
7. GenVec Expands Contract Supporting Malaria Vaccine Program
8. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
9. Lexicon Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
10. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
11. Mosaic to Present at Goldman Sachs Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Switzerland (PRWEB) , ... August 27, 2015 , ... ... on customers’ weighing needs and expertly narrows down the product choices to a ... selection criteria pares down the list to models that fit best with the ...
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... , August 26, 2015 After ... against Europlasma NV relating to P2i United States ... resolved their dispute in the United States ... on the part of either party. As a result of ... District of California dismissed the case ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2
... BERLIN, July 13 The new ... appearance. An initiative recently,launched by Germany Trade & ... namely industrial biotechnology clusters and,chemical parks, in addition ... Germany,s biotechnology sector by creating new business,opportunities across ...
... Italy, July 13 Health Robotics today announced,that ... channel strategies,with direct investments in local infrastructure at ... distributors have been negatively affected by a,number of ... distributor,s,litigation with investors, and some financial difficulties supporting ...
... NATICK, Mass., July 13 Boston Scientific Corporation ... its LATITUDE(R) Patient Management system. The LATITUDE system remotely ... both the device and a patient,s heart health status. ... visits and send relevant data directly to a patient,s physician. ...
Cached Biology Technology:German Alliance for Industrial Biotechnology Debuts in Montreal 2Health Robotics Expands and Diversifies Global Channel Strategies With Joint-Ventures & Direct Operations 2Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 2Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 3Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 4
(Date:8/24/2015)... South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and its ... with the "2015 African Biometrics Company of the Year Award". ... Nigeria .   -Cross reference: ... http://www.presseportal.de/nr/8896 - On Thursday evening, in ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... for this press release has been lifted at the request ... alligators dive, surface or roll sideways, even though they lack ... silently by using their diaphragm, pelvic, abdominal and rib muscles ... tail when they dive, toward the head when they surface ...
... Peter Glynn, a professor at the University of Miamis ... selected to receive the 2007-2008 Provosts Award for Scholarly ... and provides the recipient with a cash award toward ... Glynn, who received the award when it was first ...
... filters that help remove and transform pollutants that drain ... Scientists know this as a result of many hours ... least very wet -- monitoring streams nationwide. Nitrogen ... potential for eutrophication the excessive growth of algae ...
Cached Biology News:How alligators rock and roll 2How alligators rock and roll 3How alligators rock and roll 4How alligators rock and roll 5UM coral scientist Peter Glynn wins award for scholarly activity 2Streams natural filters, if not overloaded 2
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: